Ribociclib

From WikiMD.org
Jump to navigation Jump to search

Ribociclib (pronounced: ri-boe-SYE-klib) is a medication used in the treatment of breast cancer. It is classified under the group of drugs known as CDK4/6 inhibitors, which work by slowing down the growth of cancer cells.

Etymology

The name Ribociclib is derived from the words 'ribo' and 'ciclib'. 'Ribose' is a type of sugar found in RNA, and 'ciclib' is a suffix used for drugs that inhibit cyclin-dependent kinases (CDKs).

Usage

Ribociclib is used in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Mechanism of Action

Ribociclib is a selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6). These kinases are activated upon binding to D-cyclins. In many types of cancer, uncontrolled cell division is driven by CDK4/6-cyclin D complexes. Ribociclib inhibits the proliferation of these cancer cells by blocking the aforementioned complexes.

Side Effects

Common side effects of Ribociclib include nausea, fatigue, low levels of white blood cells, hair loss, vomiting, and diarrhea. Serious side effects may include infections, liver problems, and heart problems.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski